Trial Profile
A phase I trial to evaluate the safety of the peanut allergy vaccine in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Oct 2016
Price :
$35
*
At a glance
- Drugs SAR 439794 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Sanofi
- 02 Oct 2016 New trial record
- 28 Sep 2016 According to an Immune Design media release, first patient was dosed by Sanofi, in September 2016.